This invention relates to compounds represented by formula (I):
wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
A facile synthesis of a potent SGLT2 inhibitor, 6-deoxydapagliflozin, from methyl 2,3,4-tri-O-benzyl-6-deoxy-6-iodo-alpha-d-glucopyranoside in six steps with an overall yield of 50 % is described. The key steps were the reductive deiodination of the starting iodide under hydrogenolytic conditions to build the desired 6-deoxyglucose functionality, the coupling of 2,3,4-tri-O-benzyl-6-deoxy-d-gluconolactone and (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methane, followed by BF3 center dot Et2O-mediated reduction with Et3SiH in order to construct the desired anomeric beta-configuration. A variety of methods used for the cleavage of benzyl groups in 2,3,4-tri-O-benzyl-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1,6-dideoxy-beta-d-glucopyranose were intensively screened, leading to the discovery of AlCl3-mediated cleavage as the optimal method..